JP2017502948A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017502948A5 JP2017502948A5 JP2016539110A JP2016539110A JP2017502948A5 JP 2017502948 A5 JP2017502948 A5 JP 2017502948A5 JP 2016539110 A JP2016539110 A JP 2016539110A JP 2016539110 A JP2016539110 A JP 2016539110A JP 2017502948 A5 JP2017502948 A5 JP 2017502948A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- azabicyclo
- hexane
- naphthalen
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 claims 48
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 12
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 12
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 12
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 11
- HKHCSWPSUSWGLI-CABCVRRESA-N (1r,5s)-1-naphthalen-2-yl-3-azabicyclo[3.1.0]hexane Chemical compound C1=CC=CC2=CC([C@@]34CNC[C@H]4C3)=CC=C21 HKHCSWPSUSWGLI-CABCVRRESA-N 0.000 claims 8
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims 8
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims 7
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 6
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 4
- -1 hydroxypropoxy Chemical group 0.000 claims 3
- 239000000314 lubricant Substances 0.000 claims 3
- 235000019359 magnesium stearate Nutrition 0.000 claims 3
- 239000003607 modifier Substances 0.000 claims 3
- 239000002245 particle Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 claims 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 2
- 239000011230 binding agent Substances 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000007884 disintegrant Substances 0.000 claims 2
- 229960001021 lactose monohydrate Drugs 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 238000013268 sustained release Methods 0.000 claims 2
- 239000012730 sustained-release form Substances 0.000 claims 2
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical group CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 claims 1
- ZSLUVFAKFWKJRC-IGMARMGPSA-N 232Th Chemical compound [232Th] ZSLUVFAKFWKJRC-IGMARMGPSA-N 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 1
- 229920000881 Modified starch Polymers 0.000 claims 1
- 229920002472 Starch Polymers 0.000 claims 1
- 229910052776 Thorium Inorganic materials 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 235000010980 cellulose Nutrition 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229940049654 glyceryl behenate Drugs 0.000 claims 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 1
- 229920003130 hypromellose 2208 Polymers 0.000 claims 1
- 229940031707 hypromellose 2208 Drugs 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 1
- 239000008108 microcrystalline cellulose Substances 0.000 claims 1
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000008107 starch Substances 0.000 claims 1
- 235000019698 starch Nutrition 0.000 claims 1
- 239000000454 talc Substances 0.000 claims 1
- 229910052623 talc Inorganic materials 0.000 claims 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361913886P | 2013-12-09 | 2013-12-09 | |
| US61/913,886 | 2013-12-09 | ||
| PCT/US2014/069416 WO2015102826A1 (en) | 2013-12-09 | 2014-12-09 | Novel compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017502948A JP2017502948A (ja) | 2017-01-26 |
| JP2017502948A5 true JP2017502948A5 (https=) | 2018-01-18 |
Family
ID=53371779
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016539110A Withdrawn JP2017502948A (ja) | 2013-12-09 | 2014-12-09 | 新規な組成物 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US9839627B2 (https=) |
| EP (1) | EP3080080A4 (https=) |
| JP (1) | JP2017502948A (https=) |
| KR (1) | KR20160101012A (https=) |
| CN (1) | CN106029637A (https=) |
| AU (1) | AU2014374259A1 (https=) |
| CA (1) | CA2936108A1 (https=) |
| WO (2) | WO2015089111A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ592836A (en) | 2005-07-27 | 2013-01-25 | Dov Pharmaceutical Inc | Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders |
| US20140206740A1 (en) | 2011-07-30 | 2014-07-24 | Neurovance, Inc. | Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters |
| KR20160101012A (ko) | 2013-12-09 | 2016-08-24 | 뉴로반스, 인크. | 신규 조성물 |
| SG10201911417PA (en) | 2015-06-17 | 2020-01-30 | Otsuka America Pharmaceutical Inc | Crystalline compounds |
| WO2018119291A1 (en) * | 2016-12-21 | 2018-06-28 | Otsuka America Pharmaceutical, Inc. | Synthetic methods |
| JP7399850B2 (ja) | 2018-04-26 | 2023-12-18 | 株式会社エーピーアイ コーポレーション | 芳香族ニトリル化合物の製造方法 |
| WO2021085468A1 (ja) | 2019-10-29 | 2021-05-06 | 株式会社エーピーアイ コーポレーション | 高純度２－ナフチルアセトニトリル及びその製造方法 |
| MX2023009833A (es) | 2021-02-23 | 2023-09-04 | Otsuka Pharma Co Ltd | Formulaciones farmaceuticas de cetanafadina y metodos para prepararlas y utlizarlas. |
| US12502358B1 (en) | 2024-08-13 | 2025-12-23 | Innovate Therapeutics Llc | Centanafadine multiphasic controlled-release pharmaceutical formulation |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060223875A1 (en) | 2005-03-08 | 2006-10-05 | Phil Skolnick | Methods and compositions for production, formulation and use of 1-aryl-3-azabicyclo[3.1.0]hexanes |
| US20070082939A1 (en) | 2005-07-26 | 2007-04-12 | Lippa Arnold S | Methods and compositions for the treatment of neuropathies and related disorders |
| NZ592836A (en) * | 2005-07-27 | 2013-01-25 | Dov Pharmaceutical Inc | Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders |
| CA2641665A1 (en) * | 2006-02-10 | 2007-08-16 | Boehringer Ingelheim International Gmbh | Modified release formulation |
| NZ573174A (en) * | 2006-06-01 | 2012-01-12 | Msd Consumer Care Inc | Sustained release pharmaceutical dosage form containing phenylephrine |
| US20080058535A1 (en) | 2006-07-25 | 2008-03-06 | Zhengming Chen | Methods and compositions for production, formulation and use of 1 aryl-3-azabicyclo[3.1.0]hexanes |
| WO2009128058A1 (en) | 2008-04-18 | 2009-10-22 | UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al | Psycho-pharmaceuticals |
| EP2646019A4 (en) * | 2010-12-03 | 2014-05-21 | Euthymic Bioscience Inc | PREPARATION AND USE OF (+) - 1- (3,4-DICHLOROPHENYL) -3-AZABICYCLO- [3.1.0] HEXANE IN THE TREATMENT OF DISEASES AFFECTED BY MONOAMINE-TYPE NEUROTRANSMITTERS |
| JP2014515008A (ja) * | 2011-03-03 | 2014-06-26 | ヴァンダービルト ユニバーシティー | Ｍｇｌｕｒ５の負のアロステリック調節剤としての６−アルキル−ｎ−（ピリジン−２−イル）−４−アリールオキシピコリンアミド類似体ならびにそれを作製および使用する方法 |
| PT2819516T (pt) * | 2011-07-30 | 2020-03-25 | Otsuka America Pharmaceutical Inc | Utilização de (1r,5s)-(+)-1-(naftalen-2-il)-3-azabiciclo[3.1.0]hexano no tratamento de doenças afectadas por neurotransmissores monoaminas |
| US20140206740A1 (en) * | 2011-07-30 | 2014-07-24 | Neurovance, Inc. | Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters |
| US20140228421A1 (en) | 2011-09-07 | 2014-08-14 | Anthony McKinney | Methods For Inhibiting Native And Promiscuous Uptake Of Monoamine Neurotransmitters |
| KR20160101012A (ko) * | 2013-12-09 | 2016-08-24 | 뉴로반스, 인크. | 신규 조성물 |
| SG10201911417PA (en) * | 2015-06-17 | 2020-01-30 | Otsuka America Pharmaceutical Inc | Crystalline compounds |
-
2014
- 2014-12-09 KR KR1020167018428A patent/KR20160101012A/ko not_active Withdrawn
- 2014-12-09 US US15/102,871 patent/US9839627B2/en active Active
- 2014-12-09 EP EP14876251.1A patent/EP3080080A4/en not_active Withdrawn
- 2014-12-09 WO PCT/US2014/069401 patent/WO2015089111A1/en not_active Ceased
- 2014-12-09 CA CA2936108A patent/CA2936108A1/en not_active Abandoned
- 2014-12-09 AU AU2014374259A patent/AU2014374259A1/en not_active Abandoned
- 2014-12-09 WO PCT/US2014/069416 patent/WO2015102826A1/en not_active Ceased
- 2014-12-09 CN CN201480074992.0A patent/CN106029637A/zh active Pending
- 2014-12-09 US US15/102,949 patent/US20160303077A1/en not_active Abandoned
- 2014-12-09 JP JP2016539110A patent/JP2017502948A/ja not_active Withdrawn
-
2022
- 2022-03-10 US US17/691,911 patent/US20220347157A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017502948A5 (https=) | ||
| JP2017523206A5 (https=) | ||
| US20220347157A1 (en) | Sustained release pharmaceutical compositions comprising (1r, 5s)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane | |
| JP2011098964A5 (https=) | ||
| SG10201407947WA (en) | Compressible-coated pharmaceutical compositions and tablets and methods of manufacture | |
| JP2008501025A5 (https=) | ||
| JP2014167026A5 (https=) | ||
| JP2014532638A5 (https=) | ||
| PE20161072A1 (es) | Formulacion compuesta para administracion oral que comprende ezetimibe y rosuvastatina | |
| JP2015511635A5 (https=) | ||
| CN104661649A (zh) | 包含替格瑞洛的固态口服医药制剂 | |
| FI3756650T3 (fi) | (+)-2-[1-(3-etoksi-4-metoksifenyyli)-2-metaanisulfonyylietyyli]-4-asetyyliaminoisoindoliini-1,3-dionin formulaatioita | |
| JP2017537954A5 (https=) | ||
| AR100977A1 (es) | Formulación compuesta para la administración oral que comprende ezetimiba y rosuvastatina, y un proceso para su preparación | |
| JP2016530238A5 (https=) | ||
| US20190240158A1 (en) | Immediate release tablet of dofetilide | |
| MX356105B (es) | Formulaciones de ácido ciclopropancarboxílico de {2-[(1s)-1-(3-etoxi-4-metoxi-fenil)-2-metansulfonil-etil]-3-oxo-2 ,3-dihidro-1h-isoindol-4-il}-amida. | |
| AR066924A1 (es) | Formulacion de nevirapina de liberacion prolongada | |
| US20140199382A1 (en) | Stable pharmaceutical compositions of an s1p receptor agonist | |
| MX339136B (es) | Composicion de liberacion pulsatil de sildenafil y proceso para prepararla. | |
| JP2017502941A5 (https=) | ||
| JP2017520619A5 (https=) | ||
| JP2018515566A5 (https=) | ||
| JP2023052398A (ja) | ４－アミノ－３－ブタン酸類縁体含有固形製剤 | |
| CA2895881C (en) | Tablet composition comprising cinacalcet hydrochloride |